ASX:TLX Telix Pharmaceuticals (TLX) Stock Price, News & Analysis → The system that called 2023’s top 7 stocks is at it again… (From WealthPress) (Ad) Free TLX Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume746,789 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Telix Pharmaceuticals alerts: Email Address Ad The TradingPubAt first glance, this chart looks like nonsense…We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates”But if you want the stock with “Hotspot Dates” hitting NEXT WEEK… About Telix Pharmaceuticals Stock (ASX:TLX)Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and related medical devices for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX250-CDx that is in Phase III clinical trials for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of kidney cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase II clinical trials for the treatment of glioblastoma (brain cancer); TLX66, which is in Phase II clinical trials for the treatment of bone marrow conditioning and rare diseases; and TLX300 that is in Phase I clinical trial for the treatment and diagnosis of soft tissue sarcoma. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; and TLX599-CDx for treatment of prostate cancer imaging agent. The company was founded in 2015 and is headquartered in North Melbourne, Australia.Read More Ad Wealthpin ProOne trade. One ticker. One week. Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week? Well, then you should click here to see this free training. TLX Stock News HeadlinesApril 18, 2024 | fool.com.auWhy is the Telix share price jumping 15% to a record high?April 17, 2024 | finanznachrichten.deTelix Pharmaceuticals Limited: Q1 2024 Revenue and Business UpdateApril 23, 2024 | Wealthpin Pro (Ad)One trade. One ticker. One week. Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week? April 17, 2024 | finance.yahoo.comQ1 2024 Revenue and Business UpdateApril 16, 2024 | finance.yahoo.comQSAM ANNOUNCES REVERSE STOCK SPLIT RATIO AHEAD OF MERGERApril 15, 2024 | msn.com'Critical unmet need': Why everyone is talking about this ASX 200 healthcare stockApril 4, 2024 | msn.comWhy Aurelia Metals, Elders, GQG, and Telix shares are storming higher todayMarch 27, 2024 | finance.yahoo.comWorld First Use of Lightpoint's SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in SpainApril 23, 2024 | Wealthpin Pro (Ad)One trade. One ticker. One week. Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week? March 12, 2024 | wsj.comTelix Pharmaceuticals Ltd.March 4, 2024 | finanznachrichten.deTelix Pharmaceuticals Limited: Telix to Acquire ARTMS, Inc. and its Advanced Isotope Production PlatformFebruary 22, 2024 | msn.comInaugural profit overlooked as R&D spending soars at Telix PharmaceuticalsFebruary 22, 2024 | finance.yahoo.comTelix 2023 Full Year Results: Inaugural Profit Achieved, Strong Revenue Growth Underpins Investment in Late-stage PipelineFebruary 8, 2024 | finanznachrichten.deQSAM Biosciences Inc.: QSAM Biosciences Signs Definitive Agreement to be Acquired by Telix PharmaceuticalsFebruary 7, 2024 | finance.yahoo.comTelix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting PlatformFebruary 7, 2024 | finance.yahoo.comQSAM Biosciences Signs Definitive Agreement to be Acquired by Telix PharmaceuticalsFebruary 2, 2024 | fool.com.au2 top ASX growth shares to buy right now and hold for the long termJanuary 22, 2024 | finance.yahoo.comTelix Highlights Presentations at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2024)January 4, 2024 | finance.yahoo.comTelix Announces Planned Registered Public Offering and Listing in the United StatesJanuary 4, 2024 | finance.yahoo.comUPDATE 2-Australia's Telix Pharmaceuticals jumps on potential US listingJanuary 4, 2024 | ca.finance.yahoo.comAustralia's Telix Pharmaceuticals jumps on potential US listingJanuary 3, 2024 | finance.yahoo.comTelix to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceDecember 18, 2023 | finanznachrichten.deTelix Pharmaceuticals Limited: Telix Submits Biologics License Application (BLA) for TLX250-CDx (Zircaix) for Imaging of Kidney CancerDecember 18, 2023 | finance.yahoo.comTelix Submits Biologics License Application (BLA) for TLX250-CDx (Zircaix™) for Imaging of Kidney CancerDecember 4, 2023 | finance.yahoo.comFirst Patient Dosed in European Named Patient (Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging AgentNovember 29, 2023 | finanznachrichten.deTelix Pharmaceuticals Limited: Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCSNovember 29, 2023 | finance.yahoo.comPhase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCSSee More Headlines Receive TLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Telix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:TLX CUSIPN/A CIKN/A Webwww.telixpharma.com Phone61 4 4914 8448FaxN/AEmployees234Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A$0.02 Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$5.21 million Net Margins1.04% Pretax MarginN/A Return on Equity4.55% Return on Assets9.92% Debt Debt-to-Equity Ratio11.72 Current Ratio1.43 Quick Ratio3.00 Sales & Book Value Annual Sales$502.55 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow8.35 Book ValueA$0.46 per share Price / BookN/AMiscellaneous Outstanding Shares323,990,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta2.35 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Christian P. Behrenbruch BEng(Hons) (Age 48)DPhil(Oxon), GAICD, J.D., M.B.A., MBA, Co-Founder, MD, Group CEO & Executive Director Comp: $669.24kMr. Darren Smith B.Bus. (Age 59)FCPA, M.B.A., Group Chief Financial Officer Comp: $571.17kDr. Andreas Kluge M.D.Ph.D., Chief Medical Advisor & Non-Executive DirectorMr. Richard Valeix M.B.A.Group Chief Commercial OfficerMr. Darren PattiGroup Chief Operating OfficerDr. Michael Wheatcroft B.Sc.BSc(Hons), Ph.D., Ph.D., (Cantab), Chief ScientistMr. Craig UlrickChief Information OfficerMs. Kyahn Williamson B.A.Senior Vice President of Corporate Communications & Investor RelationsMs. Melanie Farris (AGIAACG, ACIS) BComn, B.Com., GradDip, M.A.I.C., Senior VP of Global Governance, Risk & ComplianceMs. Lena Moran-Adams L.L.B.Group General CounselMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All CompetitorsInsidersChristian BehrenbruchSold 153,298 sharesTotal: $1.69 M ($11.00/share)Christian BehrenbruchSold 120,268 sharesTotal: $356,714.89 ($2.97/share) TLX Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Telix Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Telix Pharmaceuticals investors own include ACADIA Pharmaceuticals (ACAD), Adverum Biotechnologies (ADVM), Aimmune Therapeutics (AIMT), ANI Pharmaceuticals (ANIP), AxoGen (AXGN), Biohaven (BHVN), bluebird bio (BLUE), Blueprint Medicines (BPMC), Calithera Biosciences (CALA) and Codexis (CDXS). This page (ASX:TLX) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing[Shocking] Elon Musk’s Plan To End BanksCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telix Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
